Psilocybin, the active compound in hallucinogenic mushrooms, is edging into mainstream psychiatry in parts of Europe – with Switzerland already treating patients and the Czech Republic opening tightly supervised therapies. But France is holding back, limiting its use to clinical trials while doctors wait for stronger evidence of its efficacy.
A Moscow poet highlights the challenges of speaking out against the war in Ukraine
...
Read moreDetails